Logo image of RCEL

AVITA MEDICAL INC (RCEL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RCEL - US05380C1027 - Common Stock

3.46 USD
+0.1 (+2.98%)
Last: 12/19/2025, 8:12:35 PM
3.46 USD
0 (0%)
After Hours: 12/19/2025, 8:12:35 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to RCEL. RCEL was compared to 529 industry peers in the Biotechnology industry. RCEL has a bad profitability rating. Also its financial health evaluation is rather negative. RCEL shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RCEL has reported negative net income.
In the past year RCEL has reported a negative cash flow from operations.
In the past 5 years RCEL always reported negative net income.
RCEL had a negative operating cash flow in each of the past 5 years.
RCEL Yearly Net Income VS EBIT VS OCF VS FCFRCEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -76.19%, RCEL is doing worse than 65.60% of the companies in the same industry.
Industry RankSector Rank
ROA -76.19%
ROE N/A
ROIC N/A
ROA(3y)-45.34%
ROA(5y)-41.63%
ROE(3y)-492.68%
ROE(5y)-311.81%
ROIC(3y)N/A
ROIC(5y)N/A
RCEL Yearly ROA, ROE, ROICRCEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

Looking at the Gross Margin, with a value of 84.81%, RCEL belongs to the top of the industry, outperforming 87.33% of the companies in the same industry.
RCEL's Gross Margin has improved in the last couple of years.
RCEL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5YN/A
RCEL Yearly Profit, Operating, Gross MarginsRCEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

0

2. Health

2.1 Basic Checks

RCEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
RCEL has about the same amout of shares outstanding than it did 1 year ago.
The debt/assets ratio for RCEL is higher compared to a year ago.
RCEL Yearly Shares OutstandingRCEL Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
RCEL Yearly Total Debt VS Total AssetsRCEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -9.24, we must say that RCEL is in the distress zone and has some risk of bankruptcy.
RCEL has a worse Altman-Z score (-9.24) than 71.27% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.24
ROIC/WACCN/A
WACC9.97%
RCEL Yearly LT Debt VS Equity VS FCFRCEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

RCEL has a Current Ratio of 0.67. This is a bad value and indicates that RCEL is not financially healthy enough and could expect problems in meeting its short term obligations.
RCEL has a Current ratio of 0.67. This is amonst the worse of the industry: RCEL underperforms 90.93% of its industry peers.
RCEL has a Quick Ratio of 0.67. This is a bad value and indicates that RCEL is not financially healthy enough and could expect problems in meeting its short term obligations.
RCEL has a Quick ratio of 0.55. This is amonst the worse of the industry: RCEL underperforms 91.49% of its industry peers.
Industry RankSector Rank
Current Ratio 0.67
Quick Ratio 0.55
RCEL Yearly Current Assets VS Current LiabilitesRCEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.83% over the past year.
RCEL shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.59%.
Measured over the past years, RCEL shows a very strong growth in Revenue. The Revenue has been growing by 30.02% on average per year.
EPS 1Y (TTM)18.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
Revenue 1Y (TTM)20.59%
Revenue growth 3Y30.02%
Revenue growth 5YN/A
Sales Q2Q%-12.71%

3.2 Future

RCEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.53% yearly.
Based on estimates for the next years, RCEL will show a very strong growth in Revenue. The Revenue will grow by 38.78% on average per year.
EPS Next Y36.98%
EPS Next 2Y28.4%
EPS Next 3Y23.03%
EPS Next 5Y30.53%
Revenue Next Year7.12%
Revenue Next 2Y16.89%
Revenue Next 3Y32.8%
Revenue Next 5Y38.78%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RCEL Yearly Revenue VS EstimatesRCEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
RCEL Yearly EPS VS EstimatesRCEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RCEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RCEL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCEL Price Earnings VS Forward Price EarningsRCEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCEL Per share dataRCEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as RCEL's earnings are expected to grow with 23.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.4%
EPS Next 3Y23.03%

More info and screens

0

5. Dividend

5.1 Amount

RCEL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

AVITA MEDICAL INC

NASDAQ:RCEL (12/19/2025, 8:12:35 PM)

After market: 3.46 0 (0%)

3.46

+0.1 (+2.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-11 2026-02-11/amc
Inst Owners16.73%
Inst Owner Change-32.29%
Ins Owners0.7%
Ins Owner Change2.79%
Market Cap105.50M
Revenue(TTM)72.40M
Net Income(TTM)-48.55M
Analysts80
Price Target7.04 (103.47%)
Short Float %9.96%
Short Ratio13.81
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-54.51%
Min EPS beat(2)-58.8%
Max EPS beat(2)-50.22%
EPS beat(4)1
Avg EPS beat(4)-35.89%
Min EPS beat(4)-58.8%
Max EPS beat(4)0.41%
EPS beat(8)2
Avg EPS beat(8)-27.63%
EPS beat(12)4
Avg EPS beat(12)-19.86%
EPS beat(16)8
Avg EPS beat(16)-6.57%
Revenue beat(2)0
Avg Revenue beat(2)-14.07%
Min Revenue beat(2)-20.13%
Max Revenue beat(2)-8.01%
Revenue beat(4)0
Avg Revenue beat(4)-14.13%
Min Revenue beat(4)-20.13%
Max Revenue beat(4)-8.01%
Revenue beat(8)1
Avg Revenue beat(8)-7.78%
Revenue beat(12)5
Avg Revenue beat(12)-4.45%
Revenue beat(16)8
Avg Revenue beat(16)-0.38%
PT rev (1m)-8%
PT rev (3m)-21.59%
EPS NQ rev (1m)-33.33%
EPS NQ rev (3m)-63.9%
EPS NY rev (1m)-18.29%
EPS NY rev (3m)-85.28%
Revenue NQ rev (1m)-13.05%
Revenue NQ rev (3m)-21.52%
Revenue NY rev (1m)-5.7%
Revenue NY rev (3m)-7.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.46
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.81
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS2.37
BVpS-0.22
TBVpS-0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -76.19%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.81%
FCFM N/A
ROA(3y)-45.34%
ROA(5y)-41.63%
ROE(3y)-492.68%
ROE(5y)-311.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5YN/A
F-Score3
Asset Turnover1.14
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 160.07%
Cap/Sales 4.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.67
Quick Ratio 0.55
Altman-Z -9.24
F-Score3
WACC9.97%
ROIC/WACCN/A
Cap/Depr(3y)370.65%
Cap/Depr(5y)291.06%
Cap/Sales(3y)6.11%
Cap/Sales(5y)5.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
EPS Next Y36.98%
EPS Next 2Y28.4%
EPS Next 3Y23.03%
EPS Next 5Y30.53%
Revenue 1Y (TTM)20.59%
Revenue growth 3Y30.02%
Revenue growth 5YN/A
Sales Q2Q%-12.71%
Revenue Next Year7.12%
Revenue Next 2Y16.89%
Revenue Next 3Y32.8%
Revenue Next 5Y38.78%
EBIT growth 1Y29.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.51%
EBIT Next 3Y21.18%
EBIT Next 5Y21.52%
FCF growth 1Y-16.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.62%
OCF growth 3YN/A
OCF growth 5YN/A

AVITA MEDICAL INC / RCEL FAQ

What is the ChartMill fundamental rating of AVITA MEDICAL INC (RCEL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RCEL.


What is the valuation status for RCEL stock?

ChartMill assigns a valuation rating of 1 / 10 to AVITA MEDICAL INC (RCEL). This can be considered as Overvalued.


Can you provide the profitability details for AVITA MEDICAL INC?

AVITA MEDICAL INC (RCEL) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for RCEL stock?

The Earnings per Share (EPS) of AVITA MEDICAL INC (RCEL) is expected to grow by 36.98% in the next year.